Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Etanercept , Methotrexate

"* Etanercept: 25 mg twice weekly over 16 weeks, SC~* Methotrexate: \> 7.5 mg/week and no more than 25 mg/week, PO"

DRUG

Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide

"* Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~* Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~* Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~* Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily"

Trial Locations (27)

100

Taipei

112

Taipei

807

Kaohsiung City

1000

Manila

1004

Manila

1102

Quezon City

1200

Makati City

1500

Manila

6000

Cebu

10400

Bangkok

10450

Pulau Pinang

30450

Ipoh, Perak

62250

Putrajaya

68100

Kuala Lumpur

70300

Seremban

110029

New Delhi

308433

Singapore

500082

Hyderabaad

560017

Bangalore

560034

Bangalore

Unknown

Hong Kong

400-711

Incheon

110-744

Seoul

120-752

Seoul

133-792

Seoul

137-701

Seoul

138-736

Seoul

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00422227 - Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region | Biotech Hunter | Biotech Hunter